Form 4: Cytek Biosciences Executive Barnett Reports Stock Transactions

Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• On February 18, 2025, Valerie Barnett, Chief Legal Officer of Cytek Biosciences, exercised 2,016 Restricted Stock Units (RSUs), converting them into common stock.
• Simultaneously, 786 shares of common stock were withheld by Cytek Biosciences to cover tax obligations related to the RSU vesting at a price of $5.31 per share.
• Following these transactions, Barnett directly owns 64,080 shares of Cytek Biosciences common stock and 7,394 Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions, with no inherent positive or negative implications for the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and any recent changes.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedule described (quarterly over four years) is a fairly standard vesting arrangement.
• Tax withholding upon vesting of RSUs is a common practice to cover the executive's income tax liability.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• They provide transparency to shareholders regarding executive compensation and ownership.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Beneficial Ownership, Restricted Stock Units, RSU, Valerie Barnett, Chief Legal Officer, Stock Transactions, Tax Withholding